This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by To, E. W. H. Articles by Lo, Y. M. D. Search for Related Content PubMed PubMed Citation Articles by To, E. W. H. Articles by Lo, Y. M. D.

Rapid Clearance of Plasma Epstein-Barr Virus DNA After Surgical Treatment of Nasopharyngeal Carcinoma¹

Departments of Surgery [E. W. H. T.], Chemical Pathology [K. C. A. C., L. Y. S. C., Y. M. D. L.], Clinical Oncology [S-F. L., A. T. C. C., P. J. J.], and Anatomical and Cellular Pathology [K-F. T.], The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong Special Administrative Region, China

ABSTRACT

Purpose: Circulating EBV DNA analysis has been shown to be valuable in the detection, prognostication, and monitoring of nasopharyngeal carcinoma (NPC) patients. A previous study has shown that, after radiotherapy, plasma EBV DNA levels of NPC patients would decline exponentially with a median half-life of 3.8 days. We postulate that this decline in plasma EBV DNA reflects the decrease in cancer cell population and, therefore, the rate of decline reflects the radiosensitivity of the tumor. However, this postulation would hold true only if EBV DNA is rapidly eliminated from the circulation. In this study, we determined the in vivo elimination rate of plasma EBV DNA in NPC patients.

Experimental Design: We monitored the level of plasma EBV DNA in NPC patients during and after surgical resection of NPC. The half-life of plasma EBV DNA was then calculated by plotting the natural logarithm of EBV DNA concentrations against time.

Results: The median half-life of plasma EBV DNA after surgical resection of NPC was 139 min. After a median follow-up of 6.7 days, EBV DNA was undetectable in 8 of 11 patients. One of 8 patients with undectable EBV DNA and all of the patients with detectable EBV DNA developed clinical relapse.

Conclusions: The in vivo elimination of EBV DNA is very rapid after surgical resection of NPC. The failure of complete and rapid elimination of EBV DNA from the circulation predicts disease recurrence.

This article has been cited by other articles:

				M. L. Gulley and W. Tang Laboratory Assays for Epstein-Barr Virus-Related Disease J. Mol. Diagn., July 1, 2008; 10(4): 279 - 292. [Abstract] [Full Text] [PDF]

				K.C. A. Chan, S.-F. Leung, S.-W. Yeung, A. T.C. Chan, and Y.M. D. Lo Persistent Aberrations in Circulating DNA Integrity after Radiotherapy Are Associated with Poor Prognosis in Nasopharyngeal Carcinoma Patients Clin. Cancer Res., July 1, 2008; 14(13): 4141 - 4145. [Abstract] [Full Text] [PDF]

				C. Rago, D. L. Huso, F. Diehl, B. Karim, G. Liu, N. Papadopoulos, Y. Samuels, V. E. Velculescu, B. Vogelstein, K. W. Kinzler, et al. Serial Assessment of Human Tumor Burdens in Mice by the Analysis of Circulating DNA Cancer Res., October 1, 2007; 67(19): 9364 - 9370. [Abstract] [Full Text] [PDF]

				P. J. Bastian, G. S. Palapattu, S. Yegnasubramanian, X. Lin, C. G. Rogers, L. A. Mangold, B. Trock, M. Eisenberger, A. W. Partin, and W. G. Nelson Prognostic Value of Preoperative Serum Cell-Free Circulating DNA in Men with Prostate Cancer Undergoing Radical Prostatectomy Clin. Cancer Res., September 15, 2007; 13(18): 5361 - 5367. [Abstract] [Full Text] [PDF]

				D. C. Garcia-Olmo, L. Gutierrez-Gonzalez, J. Samos, M. G. Picazo, M. Atienzar, and D. Garcia-Olmo Surgery and Hematogenous Dissemination: Comparison Between the Detection of Circulating Tumor Cells and of Tumor DNA in Plasma Before and After Tumor Resection in Rats Ann. Surg. Oncol., August 1, 2006; 13(8): 1136 - 1144. [Abstract] [Full Text] [PDF]

				K. Koyanagi, T. Mori, S. J. O'Day, S. R. Martinez, H.-J. Wang, and D. S.B. Hoon Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res., June 15, 2006; 66(12): 6111 - 6117. [Abstract] [Full Text] [PDF]

				S. J. C. Stevens, S. A. W. M. Verkuijlen, B. Hariwiyanto, Harijadi, J. Fachiroh, D. K. Paramita, I. B. Tan, S. M. Haryana, and J. M. Middeldorp Diagnostic Value of Measuring Epstein-Barr Virus (EBV) DNA Load and Carcinoma-Specific Viral mRNA in Relation to Anti-EBV Immunoglobulin A (IgA) and IgG Antibody Levels in Blood of Nasopharyngeal Carcinoma Patients from Indonesia J. Clin. Microbiol., July 1, 2005; 43(7): 3066 - 3073. [Abstract] [Full Text] [PDF]

				P. J. Bastian, G. S. Palapattu, X. Lin, S. Yegnasubramanian, L. A. Mangold, B. Trock, M. A. Eisenberger, A. W. Partin, and W. G. Nelson Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy Clin. Cancer Res., June 1, 2005; 11(11): 4037 - 4043. [Abstract] [Full Text] [PDF]

				S. Holdenrieder, P. Stieber, J. von Pawel, H. Raith, D. Nagel, K. Feldmann, and D. Seidel Circulating Nucleosomes Predict the Response to Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., September 15, 2004; 10(18): 5981 - 5987. [Abstract] [Full Text] [PDF]

				A. T.C. Chan, B. B.Y. Ma, Y.M. D. Lo, S.F. Leung, W.H. Kwan, E. P. Hui, T. S.K. Mok, M. Kam, L. S. Chan, S. K.W. Chiu, et al. Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA J. Clin. Oncol., August 1, 2004; 22(15): 3053 - 3060. [Abstract] [Full Text] [PDF]